Biotechnology company focused on the development and commercialization of therapies for serious infectious diseases.
SIGA Technologies, Inc., operates as a seasoned pharmaceutical company, specializing in the health security and infectious disease sectors within the United States. At the forefront of its product lineup is TPOXX, an oral antiviral drug designed specifically for the treatment of human smallpox disease caused by the variola virus.
In addition to its flagship product, SIGA Technologies maintains a strategic partnership with Cipla Therapeutics. This collaboration aims to foster ongoing innovation and broaden access to antibacterial medications, particularly those geared towards countering biothreats.
Founded in 1995 and headquartered in New York, New York, SIGA Technologies continues to drive advancements in pharmaceutical solutions tailored to critical health security needs. The company's commitment to excellence in infecteious disease management underscores its pivotal role in safeguarding public health.
With a robust portfolio and a dedicated focus on addressing emerging infectious threats, SIGA Technologies remains poised to contribute significantly to the ongoing advancements in global health security initiatives.